Current and Emerging Issues in Wilsons Disease
NEJM 389:922-938, Roberts,E.A. & Schilsky, M.L., 2023
Therapeutic Devices for Epilepsy
Ann Neurol 71:157-168, Fisher,R.S., 2012
Drug-Resistant Epilepsy
NEJM 365:919-26, Kwan, P.,et al, 2011
Recent Advnaces in the Treatment of Epilepsy
Arch Neurol 60:929-935, Nguyen,D.K. &Spencer,S.S., 2003
Management of Epilepsy in Adolescents and Adults
Lancet 356:323-329, Brodie,M.J. & French,J.A., 2000
Assessment of Vagus Nerve Stimulation for Epilepsy
Neurol 49:293-297, Fisher,R.S.,et al, 1997
Surgery for Seizures
NEJM 334:647-652, Engel,J.Jr., 1996
New Antiepileptic Drugs:A Systematic Review of Their Efficacy and Tolerability
BMJ 313:1169-1174, 1157, 1158996., Marson,A.G.,et al, 1996
Lentiviral Haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded access
Lancet 399:372-383, Fumagalli, F.,et al, 2022
Recent Advances in the Diagnosis and Management of Cluster Headache
BMJ 376:e059577, Schindler, E. & Burish, M.J., 2022
Spina Bifida
NEJM 387:444-450, Iskandar, B.J. & Finnell, R.H., 2022
The 5 Pillars in Tourette Syndrome Deep Brain Stimulation Patient Selection
Neurol 96:664-676, Martino, D.,et al, 2021
Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinsons Disease
NEJM 382:1926-1932, Schweitzer, J.S.,et al, 2020
Muscular Dystrophies
Lancet 394:2025-2038, Mercuri, E.,et al, 2019
Antibody-Mediated Encephalitis
NEJM 378:840-851, Dalmau, J.,et al, 2018
Autoimmune Encephalitides: A Broadening Field of Treatable Conditions
Neurologist 22:1-13, Kalman, B., 2017
Epilepsy: New Advances
Lancet 385:884-898, Moshe, S.L.,et al, 2015
Stent-Retriever Thrombectomy after Intravenous t-PA vs. t-PA Alone in Stroke
NEJM 372:DOI:10.1056/NEJMoa1415061, DOI:10.1056 NEJM e1503217, Saver, J.L.,et al, 2015
Thrombectomy within 8 Hours after Symptom Onset in Ischemic Stroke
NEJM 372:DOI:10.1056 NEJMoa1503780, DOI:1056NEJM e1503217, Jovin, T.G.,et al, 2015
Efficacy of Idebenone on Respiratory Function in Patients with Duchenne Muscular Dystrophy not using Glucocorticoids (DELOS): A Double-Blind Randomised Placebo-Controlled Phase 3 Trial
Lancet 385:1748-1757,1704, Buyse, G.M.,et al, 2015
Newer Agents in the Treatment of Multiple Sclerosis
Neurologist 19:104-117, Pawate, S. & Bagnato F., 2015
Bionic Reconstruction to Restore Hand Function After Brachial Plexus Injury: A Case Series of Three Patients
Lancet 385:2183-2189, Aszmann, O.C.,et al, 2015
Stent-Retriever Thrombectomy after Intravenous t-PA vs. t-PA Alone in Stroke
NEJM 372:2285-2295,2347, Saver, J.L.,et al, 2015
Thrombectomy within 8 hours after Symptom Onset in Ischemic Stroke
NEJM 372:2296-2306,2347, Jovin, T.G.,et al, 2015
Contemporary management and recent advances in paediatric hydrocephalus
BMJ 343:d4191, Kandasamy, J.,et al, 2011
Multiple Sclerosis Therapeutics: Unexpected Outcomes Clouding Undisputed Successes
Neurol 72:1008-1015, Wiendl,H. &Hohlfeld,R., 2009
Human Natural Autoantibodies in the Treatment of Neurologic Disease
Neurol 72:1269-1276, Rodriguez,M.,et al, 2009
Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009
Diagnosis and Management of Motor Neurone Disease
BMJ 336:658-662, McDermott,C.J. &Shaw,P.J., 2008
Effect of Laquinimod on MRI-Monitored Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IIb Study
Lancet 371:2085-2092,2059, Comi,G.,etc., 2008
Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008
Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
NEJM 359:1786-1801,1838, The CAMMS223 Trial Investigators, 2008
Neural Transplantation in Huntington Disease: Long-Term Grafts in Two Patients
Neurol 68:2093-2098, Keene,C.D.,et al, 2007
Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006
The Parkinsons Complex: Parkinsonism Is Just the Tip of the Iceberg
Ann Neurol 59:591-596, Langston,J.W., 2006
Adult Epilepsy
Lancet 367:1087-1100, Duncan,J.S.,et al, 2006
Multiple Sclerosis: New Insights and Trends
AJNR 27:954-957, Inglese,M., 2006
Multiple Sclerosis: The Role of MR Imaging
AJNR 27:1165-1176, Ge,Y., 2006
Emerging Monoclonal Antibody Therapies for Multiple Sclerosis
Neurologist 12:171-178, Cree,B., 2006
Acromegaly
NEJM 355:2558-2573, Melmed,S., 2006
The New Antiepileptic Drugs, Scientific Review
JAMA 291:605-614, LaRoche,S.M.&Helmers,S.L., 2004
Stem Cells and Neurological Disease
JNNP 74:553-557, Barker,R.A.,et al, 2003
Neuronal Regenration After Stroke
NEJM 348:2355-2356, Nadareishvili,Z. &Hallenbeck,J., 2003
Stem Cells: Do They Replace or Stimulate?
Stroke 34:2082-2083, Howells,D., 2003
Cell Therapy: Replacement
Stroke 34:2081-2082, Wechsler,L.R. &Kondziolka,D., 2003
Recent Developments in Neurology
BMJ 324:656-660, Wiebe,S.,&Nicolle,M.W., 2002
Evolving Treatment Strategies for Epilepsy
JAMA 287:2917-2920, Diaz-Arrastia,R.,et al, 2002
Cell Transplantation For Stroke
Ann Neurol 52:266-275, Savitz,S.I.,et al, 2002
New Drugs:Which Should Be Included in the Formulary?, Epilepsy:All New Drugs Should Be Included
Arch Neurol 57:272-273,275, Pierre-Louis,S.J.C., 2000